Senores Pharmaceuticals Share Price Target Tomorrow, 2025, 2030, 2035, 2040: Senores Pharmaceuticals is a fast-growing pharmaceutical company specializing in the development, manufacturing, and supply of high-quality generic medicines. The company is committed to providing affordable healthcare solutions, ensuring better access to essential medicines for patients worldwide. As of February 20, 2025, the Senores Pharmaceuticals share price on the NSE is ₹520. Below are the projected Senores Pharmaceuticals share price target for the years, 2025, 2026, 2027, 2030, 2035 And 2040.
Additionally, feel free to join our – Tele-(g)ram) where we share Fast stock market news and updates➥https://bit.ly/TradeWatch360
Senores Pharmaceuticals Company Overview
Senores Pharmaceuticals, Located in Ahmedabad, India, specializes in developing a wide variety of pharmaceutical products, including tablets, capsules, injectables, and other dosage forms. The company serves both regulated and semi-regulated markets, adhering to strict quality standards to meet global healthcare needs. With a strong focus on research and development, Senores Pharmaceuticals is dedicated to creating complex and innovative generic medicines across multiple therapeutic areas.
| Company type | Private |
| Traded as | NSE: SENORES BSE: 544319 |
| Industry | Pharmaceuticals |
| Founded | 2017; 7 years ago |
| Global Presence | Operations in the USA, India, Africa, Far East, CIS, Middle East, Latin America, and African markets. Products available in 49 countries |
| Headquarters | Ahmedabad, Gujarat, India |
| Key people | Swapnil Shah, Managing Director. Arpit Shah, Managing Director |
| Certifications | US FDA. WHO GMP. ISO. Various approvals from health authorities in countries such as Cambodia, Kenya, Kuwait, Nigeria, Peru, the Philippines, Sri Lanka, Zambia, and Liberia |
| Services | Manufactures tablets, capsules, ampoules, liquid vials, dry powder vials, and other generic Products. Specializes in oral solids, injectables, liquids, and ORS (Oral Rehydration Solutions) |
| Revenue | ₹215 crore(2024) |
| Operating income | ₹42 crore((2024) |
| Net income | ₹33 crore(2024) |
| Total assets | ₹622 crore(2024) |
| Total equity | ₹31 crore(2024) |
| Number of employees | Over 1,000 globally (2024) |
| Website | www.senorespharma.com |
Senores Pharmaceuticals Share Price Target For 2025
| Year | 1st Target | 2nd Target |
| 2025 | ₹800 | ₹950 |
By 2025, Senores Pharmaceuticals is projected to achieve a first target of ₹800 and a second target of ₹950. These growth expectations are fueled by the company’s focus on product innovation and expansion in global pharmaceutical markets. Its increasing emphasis on R&D and sustainable healthcare solutions positions it for steady progress.
Read More:- Unimech Aerospace Share Price Target 2025, 2030, 2035, 2040
Senores Pharmaceuticals Share Price Target For 2026
| Year | 1st Target | 2nd Target |
| 2026 | ₹1150 | ₹1300 |
In 2026, the share price is estimated to reach ₹1,150 (1st Target) and ₹1,300 (2nd Target). The company’s operational efficiency and efforts to expand its global footprint, especially in key therapeutic areas, are expected to drive this growth. Strategic partnerships and government healthcare initiatives further strengthen its market position.
Senores Pharmaceuticals Share Price Target For 2027
| Year | 1st Target | 2nd Target |
| 2027 | ₹1400 | ₹1650 |
By 2027, Senores Pharmaceuticals could achieve ₹1,400 (1st Target) and ₹1,650 (2nd Target). The company’s strong financial performance, coupled with its ability to cater to growing healthcare demands, ensures a stable upward trajectory. Its commitment to innovation in pharmaceuticals is a key growth driver.
Senores Pharmaceuticals Share Price Target For 2028
| Year | 1st Target | 2nd Target |
| 2028 | ₹1750 | ₹1900 |
For 2028, the share price is forecasted to reach ₹1,750 (1st Target) and ₹1,900 (2nd Target). Senores Pharmaceuticals investment in advanced manufacturing and expanding its product portfolio globally are expected to yield substantial returns. Its focus on emerging markets further enhances its growth potential.
Senores Pharmaceuticals Share Price Target For 2029
| Year | 1st Target | 2nd Target |
| 2029 | ₹2000 | ₹2150 |
By 2029, the company share price is projected to touch ₹2,000 (1st Target) and ₹2,150 (2nd Target). This reflects Senores Pharmaceuticals strategic execution of its long-term goals, including deeper penetration into specialty medicines and continued emphasis on sustainability in operations.
Senores Pharmaceuticals Share Price Target For 2030
| Year | 1st Target | 2nd Target |
| 2030 | ₹2300 | ₹2500 |
Looking ahead to 2030, the share price is estimated to climb to ₹2,300 (1st Target) and ₹2,500 (2nd Target). The company’s diversified portfolio and expansion into new markets, along with its focus on advanced pharmaceutical technologies, are likely to sustain this growth momentum.
Senores Pharmaceuticals Share Price Target For 2035
| Year | 1st Target | 2nd Target |
| 2035 | ₹3500 | ₹4350 |
By 2035, Senores Pharmaceuticals is expected to achieve ₹3,500 (1st Target) and ₹4,350 (2nd Target). The company’s continued leadership in pharmaceutical innovation and its strategic growth initiatives in global healthcare markets ensure its position as a top player in the industry.
Read More: Carraro India Share Price Target Tomorrow, 2025, 2030, 2035, 2040
Senores Pharmaceuticals Share Price Target For 2040
| Year | 1st Target | 2nd Target |
| 2040 | ₹5000 | ₹6150 |
By 2040, the share price could soar to ₹5,000 (1st Target) and ₹6,150 (2nd Target). Senores Pharmaceuticals investments in cutting-edge technologies, focus on sustainability, and leadership in global healthcare advancements are anticipated to drive significant long-term growth, making it a leader in its sector.
Senores Pharmaceuticals Share Price Target Forecast 2025 to 2040
| Year | Year-High Target (₹) | Year-Low Target (₹) |
| 2025 | ₹950 | ₹500 |
| 2026 | ₹1300 | ₹850 |
| 2027 | ₹1650 | ₹1100 |
| 2028 | ₹1900 | ₹1350 |
| 2029 | ₹2150 | ₹1600 |
| 2030 | ₹2500 | ₹1800 |
| 2035 | ₹4350 | ₹2250 |
| 2040 | ₹6150 | ₹3500 |
Senores Pharmaceuticals Peer comparison
| Sector: Pharmaceuticals | Industry: Pharmaceuticals – Indian – Formulations | ||||
| Name | P/E | Mar Cap ₹Cr. | Div Yld% | NP Qtr ₹Cr. | ROCE% |
| Torrent Pharma. | 65.93 | 114732.93 | 0.83 | 453.00 | 23.16 |
| Ajanta Pharma | 42.76 | 37419.30 | 1.20 | 216.48 | 31.60 |
| Gland Pharma | 42.38 | 29314.27 | 1.11 | 163.53 | 13.58 |
| Caplin Point Lab | 38.47 | 18974.41 | 0.19 | 130.81 | 26.46 |
| ERIS Lifescience | 53.34 | 18520.39 | 0.00 | 96.35 | 11.27 |
| Sai Life | 182.90 | 15143.74 | 0.00 | 28.01 | 10.57 |
| Marksans Pharma | 37.77 | 13073.77 | 0.20 | 97.76 | 20.61 |
| Senores Pharma. | 57.20 | 1800.70 | 11.53 | ||
Senores Pharmaceuticals Ltd Fundamentals
| Parameter | Value |
| Market Cap | ₹2569 Cr |
| P/E Ratio (TTM) | 81.67 |
| P/B Ratio | 3.63 |
| Industry P/E | 37.93 |
| Debt to Equity | 1.26 |
| ROE | 15.40% |
| EPS (TTM) | 6.83 |
| Dividend Yield | 0.00% |
| 52 Week High | ₹609 |
| 52 Week Low | ₹538 |
| Book Value | ₹153.52 |
| Face Value | 10 |
Senores Pharmaceuticals Financial Results
| Number In ₹Cr | Mar 2022 | Mar 2023 | Mar 2024 |
| Sales | 14 | 35 | 215 |
| Expenses | 12 | 23 | 173 |
| Operating Profit | 2 | 13 | 42 |
| OPM % | 14% | 36% | 19% |
| Other Income | 0 | 4 | 3 |
| Interest | 1 | 2 | 9 |
| Depreciation | 1 | 2 | 10 |
| Profit before tax | 1 | 12 | 25 |
| Tax % | 13% | 32% | -31% |
| Net Profit | 1 | 8 | 33 |
| EPS in Rs | |||
| Dividend Payout % | 0% | 0% | 0% |
Senores Pharmaceuticals Balance Sheet
| Number In ₹Cr | Mar 2022 | Mar 2023 | Mar 2024 |
| Equity Capital | 9 | 10 | 31 |
| Reserves | 28 | 36 | 174 |
| Borrowings | 15 | 63 | 258 |
| Other Liabilities | 8 | 23 | 160 |
| Total Liabilities | 59 | 131 | 622 |
| Fixed Assets | 7 | 27 | 235 |
| CWIP | 8 | 34 | 97 |
| Investments | 15 | 16 | 0 |
| Other Assets | 29 | 53 | 289 |
| Total Assets | 59 | 131 | 622 |
Senores Pharmaceuticals Shareholding Pattern
| Number In % | Jul 2024 | Dec 2024 |
| Promoters | 66.66% | 45.76% |
| Flls | 0% | 5.51% |
| Dlls | 0% | 14.97% |
| Public | 33.34% | 33.75% |
FAQs
Q.1. What is the share price target for Senores Pharmaceuticals in 2025?
Ans: In 2025, Senores Pharmaceuticals share price might go up to ₹900 (1st Target) or even ₹1050 (2nd Target). The company is growing because it helps with healthcare innovation and provides quality medicines worldwide.
Q.2. What are the projected share price targets for Senores Pharmaceuticals in 2026?
Ans: By 2026, the share price could reach ₹1250 (1st Target) and ₹1400 (2nd Target). This growth is expected as the company introduces more medicines and expands its market, especially in areas needing better healthcare solutions.
Q.3. What is the anticipated share price target for Senores Pharmaceuticals in 2027?
Ans: In 2027, the share price may climb to ₹1550 (1st Target) or ₹1650 (2nd Target). Senores Pharmaceuticals is focusing on creating advanced drugs and improving its production process, making it a stronger company.
Q.4. What are the share price targets for Senores Pharmaceuticals in 2028?
Ans: By 2028, Senores Pharmaceuticals share price might hit ₹1750 (1st Target) and ₹1900 (2nd Target). This reflects their success in making medicines affordable and increasing their presence in global markets.
Q.5. What is the forecast for Senores Pharmaceuticals share price in 2029?
Ans: In 2029, the company share price might grow further to ₹2000 (1st Target) or even ₹2150 (2nd Target). This growth is due to its efforts in expanding research and development to create breakthrough treatments.
Q.6. What are the share price targets for Senores Pharmaceuticals in 2030?
Ans: By 2030, the share price could reach ₹2300 (1st Target) and ₹2500 (2nd Target). With a strong focus on healthcare innovation and global partnerships, Senores Pharmaceuticals is set to make an even bigger impact.
Q.7. What are the long-term share price targets for Senores Pharmaceuticals in 2035?
Ans: Looking forward to 2035, the share price might touch ₹3500 (1st Target) or ₹4350 (2nd Target). The company will continue to lead in the pharmaceutical industry by introducing new drugs and improving global healthcare access.
Q.8. What is the share price target for Senores Pharmaceuticals in 2040?
Ans: By 2040, Senores Pharmaceuticals share price might soar to ₹5000 (1st Target) and ₹6150 (2nd Target). Its investments in advanced technology and commitment to making healthcare better worldwide will ensure its long-term success.
Q.9. Who is the CEO of Senores Pharmaceuticals?
Ans: Senores Pharmaceuticals does not currently have a designated Chief Executive Officer (CEO). The company is led by Swapnil Shah, who serves as the Group Managing Director.
Q.10. Is there a difference between a CEO and a Group Managing Director?
Ans: Yes, there is a difference. While a CEO is typically the highest-ranking executive in a company, a Group Managing Director often has similar responsibilities but may focus more on operational leadership and implementation of strategic goals.
TradeWatch360 is a premier platform dedicated to providing real-time insights, trends, and updates in the stock market. It is designed to support both new and seasoned investors by delivering timely and actionable information across a range of asset classes, including stocks, futures, commodities, and global markets.